Brief: Intratumoral Injection Of Phio’S Ph-762 Significantly Inhibits Tumor Growth In Murine Tumor Models And May Generate Memory-Specific T Cells
22/04/2024 18:15
April 22 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* INTRATUMORAL INJECTION OF PHIO’S PH-762 SIGNIFICANTLY
INHIBITS
TUMOR GROWTH IN MURINE TUMOR MODELS AND MAY GENERATE
MEMORY-SPECIFIC T CELLS
* PHIO PHARMACEUTICALS CORP - INJECTION IN MURINE TUMORS
SHOWS
COMPOUND IS WELL TOLERATED
Source text for Eikon: ID:nGNX3WvjyT
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing